An Interventional, Multicentre, Phase IV, Single-Arm, Open-Label Study to Investigate the Efficacy and Safety of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease
Latest Information Update: 06 Dec 2024
Price :
$35 *
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Renal failure
- Focus Adverse reactions
- Sponsors AstraZeneca
- 30 Sep 2024 New trial record